Predictive Markers for the Response to 5-fluorouracil Therapy in Cancer Cells: Constant-field Gel Electrophoresis As a Tool for Prediction of Response to 5-fluorouracil-based Chemotherapy

Overview

Journal Oncol Lett

Specialty Oncology

Date 2012 Dec 21

PMID 23255942

Citations 10

Authors

E M Saleh

R A El-Awady

N Anis

Affiliations

Soon will be listed here.

Abstract

The prediction of response or severe toxicity and therapy individualisation are extremely important in cancer chemotherapy. There are few tools to predict chemoresponse or toxicity in cancer patients. We investigated the correlation between the induction and repair of DNA double-strand breaks (DSBs) using constant-field gel electrophoresis (CFGE) and evaluating cell cycle progression and the sensitivity of four cancer cell lines to 5-fluorouracil (5FU). Using a sulphorhodamine-B assay, colon carcinoma cells (HCT116) were found to be the most sensitive to 5FU, followed by liver carcinoma cells (HepG2) and breast carcinoma cells (MCF-7). Cervical carcinoma cells (HeLa) were the most resistant. As measured by CFGE, DSB induction, but not residual DSBs, exhibited a significant correlation with the sensitivity of the cell lines to 5FU. Flow cytometric cell cycle analysis revealed that 14% of HCT116 or HepG2 cells and 2% of MCF-7 cells shifted to sub-G1 phase after a 96-h incubation with 5FU. Another 5FU-induced cell cycle change in HCT116, HepG2 and MCF-7 cells was the mild arrest of cells in G1 and/or G2/M phases of the cell cycle. In addition, 5FU treatment resulted in the accumulation of HeLa cells in the S and G2/M phases. Determination of Fas ligand (Fas-L) and caspase 9 as representative markers for the extrinsic and intrinsic pathways of apoptosis, respectively, revealed that 5FU-induced apoptosis in HCT116 and HepG2 results from the expression of Fas-L (extrinsic pathway). Therefore, the induction of DNA DSBs by 5FU, detected using CFGE, and the induction of apoptosis are candidate predictive markers that may distinguish cancer cells which are likely to benefit from 5FU treatment and the measurement of DSBs using CFGE may aid the prediction of clinical outcome.

Citing Articles

Computational analysis of 5-fluorouracil anti-tumor activity in colon cancer using a mechanistic pharmacokinetic/pharmacodynamic model.

Ma C, Almasan A, Gurkan-Cavusoglu E PLoS Comput Biol. 2022; 18(11):e1010685.

PMID: 36395103 PMC: 9671373. DOI: 10.1371/journal.pcbi.1010685.

Synergistic Interactions of 5-Fluorouracil with Inhibitors of Protein Kinase CK2 Correlate with p38 MAPK Activation and FAK Inhibition in the Triple-Negative Breast Cancer Cell Line.

Winska P, Karatsai O, Staniszewska M, Koronkiewicz M, Chojnacki K, Redowicz M Int J Mol Sci. 2020; 21(17).

PMID: 32872257 PMC: 7504329. DOI: 10.3390/ijms21176234.

Antioxidant and anticancer activities of Trigonella foenum-graecum, Cassia acutifolia and Rhazya stricta.

Al-Dabbagh B, Elhaty I, Al Hrout A, Al Sakkaf R, El-Awady R, Ashraf S BMC Complement Altern Med. 2018; 18(1):240.

PMID: 30134897 PMC: 6103858. DOI: 10.1186/s12906-018-2285-7.

Inhibition of exosome release by ketotifen enhances sensitivity of cancer cells to doxorubicin.

Khan F, Saleh E, Alawadhi H, Harati R, Zimmermann W, El-Awady R Cancer Biol Ther. 2017; 19(1):25-33.

PMID: 29244610 PMC: 5790333. DOI: 10.1080/15384047.2017.1394544.

Combination treatment with 6-mercaptopurine and allopurinol in HepG2 and HEK293 cells - Effects on gene expression levels and thiopurine metabolism.

Haglund S, Vikingsson S, Almer S, Soderman J PLoS One. 2017; 12(3):e0173825.

PMID: 28278299 PMC: 5344510. DOI: 10.1371/journal.pone.0173825.

References

Pettersen H, Visnes T, Vagbo C, Svaasand E, Doseth B, Slupphaug G . UNG-initiated base excision repair is the major repair route for 5-fluorouracil in DNA, but 5-fluorouracil cytotoxicity depends mainly on RNA incorporation. Nucleic Acids Res. 2011; 39(19):8430-44. PMC: 3201877. DOI: 10.1093/nar/gkr563. View

El-Awady R, Dikomey E, Dahm-Daphi J . Radiosensitivity of human tumour cells is correlated with the induction but not with the repair of DNA double-strand breaks. Br J Cancer. 2003; 89(3):593-601. PMC: 2394378. DOI: 10.1038/sj.bjc.6601133. View

Saleh E, El-Awady R, Abdel Alim M, Abdel Wahab A . Altered expression of proliferation-inducing and proliferation-inhibiting genes might contribute to acquired doxorubicin resistance in breast cancer cells. Cell Biochem Biophys. 2009; 55(2):95-105. DOI: 10.1007/s12013-009-9058-3. View

Zhang N, Yin Y, Xu S, Chen W . 5-Fluorouracil: mechanisms of resistance and reversal strategies. Molecules. 2008; 13(8):1551-69. PMC: 6244944. DOI: 10.3390/molecules13081551. View

Longley D, Latif T, Boyer J, Allen W, Maxwell P, Johnston P . The interaction of thymidylate synthase expression with p53-regulated signaling pathways in tumor cells. Semin Oncol. 2003; 30(3 Suppl 6):3-9. DOI: 10.1016/s0093-7754(03)00119-2. View

van Triest B, Pinedo H, van Hensbergen Y, Smid K, Telleman F, Schoenmakers P . Thymidylate synthase level as the main predictive parameter for sensitivity to 5-fluorouracil, but not for folate-based thymidylate synthase inhibitors, in 13 nonselected colon cancer cell lines. Clin Cancer Res. 1999; 5(3):643-54. View

Arnold C, Goel A, Boland C . Role of hMLH1 promoter hypermethylation in drug resistance to 5-fluorouracil in colorectal cancer cell lines. Int J Cancer. 2003; 106(1):66-73. DOI: 10.1002/ijc.11176. View

Redon C, Nakamura A, Martin O, Parekh P, Weyemi U, Bonner W . Recent developments in the use of γ-H2AX as a quantitative DNA double-strand break biomarker. Aging (Albany NY). 2011; 3(2):168-74. PMC: 3082012. DOI: 10.18632/aging.100284. View

Iliakis G, Cicilioni O, Metzger L . Measurement of DNA double-strand breaks in CHO cells at various stages of the cell cycle using pulsed field gel electrophoresis: calibration by means of 125I decay. Int J Radiat Biol. 1991; 59(2):343-57. DOI: 10.1080/09553009114550321. View

10.

Sinicrope F, Yang Z . Prognostic and predictive impact of DNA mismatch repair in the management of colorectal cancer. Future Oncol. 2011; 7(3):467-74. PMC: 3770934. DOI: 10.2217/fon.11.5. View

11.

Sargent D, Sobrero A, Grothey A, OConnell M, Buyse M, Andre T . Evidence for cure by adjuvant therapy in colon cancer: observations based on individual patient data from 20,898 patients on 18 randomized trials. J Clin Oncol. 2009; 27(6):872-7. PMC: 2738431. DOI: 10.1200/JCO.2008.19.5362. View

12.

El-Awady R, Saleh E, Dahm-Daphi J . Targeting DNA double-strand break repair: is it the right way for sensitizing cells to 5-fluorouracil?. Anticancer Drugs. 2010; 21(3):277-87. DOI: 10.1097/CAD.0b013e328334b0ae. View

13.

Xiao Z, Xue J, Sowin T, Rosenberg S, Zhang H . A novel mechanism of checkpoint abrogation conferred by Chk1 downregulation. Oncogene. 2004; 24(8):1403-11. DOI: 10.1038/sj.onc.1208309. View

14.

Miyashita T, Krajewski S, Krajewska M, Wang H, Lin H, Liebermann D . Tumor suppressor p53 is a regulator of bcl-2 and bax gene expression in vitro and in vivo. Oncogene. 1994; 9(6):1799-805. View

15.

Longley D, Johnston P . Molecular mechanisms of drug resistance. J Pathol. 2005; 205(2):275-92. DOI: 10.1002/path.1706. View

16.

Pino M, Chung D . Microsatellite instability in the management of colorectal cancer. Expert Rev Gastroenterol Hepatol. 2011; 5(3):385-99. DOI: 10.1586/egh.11.25. View

17.

Miura K, Kinouchi M, Ishida K, Fujibuchi W, Naitoh T, Ogawa H . 5-fu metabolism in cancer and orally-administrable 5-fu drugs. Cancers (Basel). 2013; 2(3):1717-30. PMC: 3837334. DOI: 10.3390/cancers2031717. View

18.

Koopman M, Venderbosch S, Nagtegaal I, van Krieken J, Punt C . A review on the use of molecular markers of cytotoxic therapy for colorectal cancer, what have we learned?. Eur J Cancer. 2009; 45(11):1935-49. DOI: 10.1016/j.ejca.2009.04.023. View

19.

Helleday T, Petermann E, Lundin C, Hodgson B, Sharma R . DNA repair pathways as targets for cancer therapy. Nat Rev Cancer. 2008; 8(3):193-204. DOI: 10.1038/nrc2342. View

20.

Shi X, Liu S, Kleeff J, Friess H, Buchler M . Acquired resistance of pancreatic cancer cells towards 5-Fluorouracil and gemcitabine is associated with altered expression of apoptosis-regulating genes. Oncology. 2002; 62(4):354-62. DOI: 10.1159/000065068. View